1. Please check and comment entries here.
Table of Contents

    Topic review

    Neurological Functions of Bile Acids

    View times: 4
    Submitted by: Yoshimitsu Kiiriyama

    Definition

    Bile acids (BA) are amphipathic steroid acids synthesized from cholesterol in the liver. They act as detergents to expedite the digestion and absorption of dietary lipids and lipophilic vitamins. BA are also considered to be signaling molecules, being ligands of nuclear and cell-surface receptors, including farnesoid X receptor and Takeda G-protein receptor 5. Moreover, BA also activate ion channels, including the bile acid-sensitive ion channel and epithelial Na+ channel. BA regulate glucose and lipid metabolism by activating these receptors in peripheral tissues, such as the liver and brown and white adipose tissue. Recently, 20 different BA have been identified in the central nervous system. Furthermore, BA affect the function of neurotransmitter receptors, such as the muscarinic acetylcholine receptor and γ-aminobutyric acid receptor. BA are also known to be protective against neurodegeneration. 

    1. Introduction

    Bile acids (BA) are synthesized from cholesterol in the liver and are a significant component of bile. They are stored in the gallbladder and released into the small intestine after a meal. BA are amphipathic steroid acids and are known as indispensable detergents, expediting the digestion and absorption of dietary lipids and lipophilic vitamins by forming micelles in the small intestine. Recently, they have also been considered to be signaling molecules. They are now recognized as ligands of farnesoid X receptor (FXR), a nuclear hormone receptor, and Takeda G-protein receptor 5 (TGR5), a G-protein-coupled receptor (GPCR) that is also known as G protein-coupled bile acid receptor 1 (GPBAR1) [1].
    Bile salt composition of a variety of vertebrate species is validated. Bile salts include C27 bile alcohols, C27 bile acids, and C24 bile acids. C24 bile acids exist in all vertebrates, although C27 bile alcohols and C27 bile acids exist in fish, amphibians, reptiles, and birds [2]. 5α-C27 bile alcohol sulfates are considered as the first ancestral bile salts. 5α-cyprinol sulfate is 5α-C27 bile alcohol sulfate and activates FXR from the frog and the zebrafish, but not from the human and the mouse. In contrast, taurochenodeoxycholic acid (TCDCA) and lithocholic acid (LCA) activate FXR from the human and the mouse, but not from the frog and the zebrafish. Thus, the structure of FXR may be changed to adapt to bind species-specific bile salts [3].

    2. Neurological Functions of BA

    Twenty different BA and their receptors have been identified in the brain, implying that BA have physiological and pathophysiological roles in this tissue (Figure 2), and indeed, many studies of their physiological roles in the brain have been reported.
    Figure 2. Protective functions of bile acids (BA) against neurodegeneration. BA are known to prevent the accumulation of amyloid β peptides in Alzheimer’s disease; protect against mitochondrial damage in Parkinson’s disease; protect against apoptosis, mitochondrial damage, and ubiquitin accumulation in Huntington’s disease; and protect against apoptosis in amyotrophic lateral sclerosis.

    2.1. The Role of BA in the Brain

    BA affect the functioning of the receptors for several neurotransmitters, including M2 and M3 muscarinic acetylcholine receptors, γ-aminobutyric acid (GABA) type A (GABAA) receptors, and N-methyl-D-aspartate (NMDA) receptors. TCA, GDCA, and TDCA activate the M2 receptor, while DCA activates the M3 receptor. M2 receptors are distributed throughout the brain and are crucial for cognitive function. However, M3 receptors are localized to neurons, which project to regions such as the hippocampus and substantia nigra, although they are also expressed at low levels throughout the brain. Thus, BA may affect cognitive function, memory, and learning [4]. NMDA receptors are ionotropic glutamate receptors that are activated by the simultaneous binding of both glutamate and D-serine or glycine [5][6]. Their activation causes Ca2+ influx, which can induce long-term potentiation and long-term depression. Therefore, appropriate NMDA receptor activation is important for learning and memory [7]. In contrast, the GABAA receptor is an ionotropic GABA receptor that is a ligand-gated chloride ion channel. The activation of GABAA receptor causes an influx of chloride ions, leading to the hyperpolarization of neurons and the inhibition of neurotransmission [8]. CDCA, DCA, and CA block both GABAA and NMDA receptors [9]. Histaminergic neurons in the tuberomammillary nucleus (TMN) of the hypothalamus play an important role in arousal and wakefulness [10] and express GABAA receptors; thus, the suppression of histaminergic neuronal activation in the TMN by GABA induces sleep [11]. Conversely, UDCA increases arousal by blocking GABAA receptors on TMN neurons [12]. Moreover, a recent study has demonstrated that TUDCA can induce neurogenesis in adult rats [13]. Adult neurogenesis is the process of generating new functional neurons that are added to the adult brain and occurs in two specific regions: The subgranular zone (SGZ) of the dentate gyrus (DG) in the hippocampus and the subventricular zone (SVZ), located in the walls of the lateral ventricles. Neural stem cells (NSCs) in the SGZ of adult mammals generate neurons in the DG. NSCs in adult human SVZ may produce functional neurons in the striatum by migrating there. In contrast, NSCs in adult rodent SVZ may produce functional neurons in the olfactory bulb [14]. In the rat, TUDCA increases the proliferation and neural differentiation of NSCs in the SVZ, but not in the DG [13].

    2.2. The Role of BA in Neurodegenerative Diseases

    Alzheimer’s disease is characterized by memory loss, dementia, and morphological changes in the brain and is a common progressive neurodegenerative disease. The main pathological feature of the brains of patients with Alzheimer’s disease is the accumulation of amyloid β peptides and tangles of tau protein [15]. The processing of amyloid precursor protein (APP) by β and γ secretases generates amyloid β peptide [16][17] and the γ secretase complex includes presenilin 1 (PS1), which is associated with the maturation of V-ATPase, responsible for the acidification of lysosomes. PS1 dysfunction, thus, leads to an impairment in lysosomal acidification and function [18][19]. The accumulation of amyloid β peptides is relevant to the dysfunction of both APP and γ secretase, and APP/PS1 double knockout mice, which express both mutated human APP and PS1, are used as a model of Alzheimer’s disease. Interestingly, TUDCA reduces the accumulation of amyloid β peptides in the hippocampus and frontal cortex and rescues memory deficits in APP/PS1 double knockout mice [20][21]. In humans, plasma CA concentrations in patients with Alzheimer’s disease are significantly lower than those in control subjects, and the TCA concentration in the brain of patients with Alzheimer’s disease is also significantly lower [22]. In contrast, the plasma concentration of LCA, a secondary BA, is significantly higher in patients with Alzheimer’s disease than in controls [23]. Furthermore, it has been shown that the ratio of DCA (secondary BA) to CA (primary BA) in serum is significantly higher in Alzheimer’s patients [24]. These studies indicate the relationship between BA and Alzheimer’s disease, and the importance of the brain-gut-microbiome axis. However, morphological and functional abnormalities in mitochondria have also been identified in patients with Alzheimer’s disease [25][26]. In fibroblasts from Alzheimer’s disease patients, the mitochondrial membrane potential (MMP) is lower, and there is mitochondrial elongation. Dynamin-related protein 1 (DRP1) plays an important role in mitochondrial fission and is essential for mitochondrial quality control [27]. Although the expression of DRP1 is lower in fibroblasts from Alzheimer’s disease patients, UDCA increases its expression [28].
    Parkinson’s disease is another common progressive neurodegenerative disease that is characterized by tremors, muscle stiffness, loss or impairment of voluntary movements, slowness of movement, and postural instability [29]. Mutations in phosphatase and tensin homolog-induced putative kinase 1 (PINK1) and parkin are found in early-onset Parkinson’s disease and are important in the progression of Parkinsonism [30][31][32][33]. PINK1 and parkin initiate mitophagy and nuclear dot protein 52 kDa (NDP52), and optineurin are essential for this process [34][35]. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and rotenone treatment have been widely used in the creation of a model of Parkinson’s disease. Both toxins inhibit complex I in mitochondria, leading to neuronal mitochondrial damage and Parkinsonism [36][37]. However, TUDCA protects neurons from MPTP-induced oxidative stress and neurotoxicity in the midbrain and striatum of mice [38]. TUDCA induces nuclear factor erythroid 2-related factor 2 (Nrf2) expression and reduces the generation of reactive oxygen species, and indeed, this anti-oxidant effect of TUDCA may be Nrf2-dependent [39]. Moreover, TUDCA ameliorates clinical signs induced by MPTP, such as the increase in swimming latency, foot-dragging, and tremors. In addition, TUDCA inhibits the loss of dopaminergic neurons and reduces the loss of MMP and mitochondrial mass elicited by MPTP [40]. Furthermore, TUDCA increases the expression of PINK1, parkin, and the ratio of LC3-II/lC3-I, implying that TUDCA induces mitophagy [41]. In addition, in the rotenone-induced rat model of Parkinson’s disease, UDCA ameliorates abnormalities in the mitochondria of striatal neurons, such as irregular swelling and loss of cristae [42].
    Huntington’s disease is an autosomal dominant inherited neurodegenerative disease caused by a CAG trinucleotide expansion encoding polyglutamine (polyQ) at the N-terminus of Huntingtin (HTT). Huntington’s disease is characterized by motor dysfunction, cognitive decline, and psychiatric disturbances [43][44]. Chemical and genetic models of Huntington’s disease have been studied [45][46]. Firstly, 3-nitropropionic acid (3-NP) is an inhibitor of succinate dehydrogenase (complex II) in mitochondria and induces degeneration of the caudate-putamen, which is also present in Huntington’s disease [45]. 3-NP treatment is associated with swelling of striatal mitochondria, abnormal mitochondrial membrane structure, and apoptosis. However, TUDCA prevents mitochondrial damage and apoptosis and ameliorates the sensorimotor deficits induced by 3-NP [47]. Secondly, R6/2 transgenic mice possess a genomic fragment containing exon 1 of the human Huntingtin gene, which carries 144 CAG repeats, and are the most widely used model of Huntington’s disease [46][48]. In these mice, TUDCA prevents the striatal apoptosis and cerebral and striatal atrophy [49]. The accumulation of HTT and ubiquitin are also symptoms of Huntington’s disease, and ubiquitin is recruited to polyglutamine-expanded HTT fragments [50]. TUDCA reduces the accumulation of ubiquitin in the striatum of R6/2 transgenic mice and ameliorates their sensorimotor deficits [49].
    Amyotrophic lateral sclerosis (ALS) is a progressive and ultimately fatal disease that is characterized by the degeneration of both upper and lower motor neurons, leading to muscle weakness, atrophy, and paralysis [51]. Impairments in superoxide dismutase 1 (SOD1), C9ORF72, TAR DNA-binding protein of 43 kDa (TDP-43), and fused in sarcoma (FUS) are molecular features of this disease [52]. Transgenic mice that carry the glycine 93 to alanine mutation of human SOD1 (hSOD1G93A) are the most studied model of ALS [53]. NSC-34 cells carrying hSOD1G93A also represent a useful model of ALS-affected motor neurons [54]. Glycoursodeoxycholic acid (GUDCA) prevents the apoptosis of NSC-34 cells carrying hSOD1G93A [55], and clinical trials of the use of TUDCA in patients with ALS have shown an improvement in muscle function and survival time, without adverse effects [56].

    The entry is from 10.3390/biom9060232

    References

    1. Thomas, C.; Pellicciari, R.; Pruzanski, M.; Auwerx, J.; Schoonjans, K. Targeting bile-acid signalling for metabolic diseases. Nat. Rev. Drug Discov. 2008, 7, 678–693.
    2. Hofmann, A.F.; Hagey, L.R.; Krasowski, M.D. Bile salts of vertebrates: Structural variation and possible evolutionary significance. J. Lipid Res. 2010, 51, 226–246.
    3. Reschly, E.J.; Ai, N.; Ekins, S.; Welsh, W.J.; Hagey, L.R.; Hofmann, A.F.; Krasowski, M.D. Evolution of the bile salt nuclear receptor FXR in vertebrates. J. Lipid Res. 2008, 49, 1577–1587.
    4. Abrams, P.; Andersson, K.E.; Buccafusco, J.J.; Chapple, C.; de Groat, W.C.; Fryer, A.D.; Kay, G.; Laties, A.; Nathanson, N.M.; Pasricha, P.J.; et al. Muscarinic receptors: Their distribution and function in body systems, and the implications for treating overactive bladder. Br. J. Pharmacol. 2006, 148, 565–578.
    5. Kiriyama, Y.; Nochi, H. D-Amino Acids in the Nervous and Endocrine Systems. Scientifica (Cairo) 2016, 2016, 6494621.
    6. Montes de Oca Balderas, P. Flux-Independent NMDAR Signaling: Molecular Mediators, Cellular Functions, and Complexities. Int. J. Mol. Sci. 2018, 19, 3800.
    7. Kumar, A. NMDA Receptor Function During Senescence: Implication on Cognitive Performance. Front. Neurosci. 2015, 9, 473.
    8. Cicek, S.S. Structure-Dependent Activity of Natural GABA(A) Receptor Modulators. Molecules 2018, 23, 1512.
    9. Schubring, S.R.; Fleischer, W.; Lin, J.S.; Haas, H.L.; Sergeeva, O.A. The bile steroid chenodeoxycholate is a potent antagonist at NMDA and GABA(A) receptors. Neurosci. Lett. 2012, 506, 322–326.
    10. Fujita, A.; Bonnavion, P.; Wilson, M.H.; Mickelsen, L.E.; Bloit, J.; de Lecea, L.; Jackson, A.C. Hypothalamic Tuberomammillary Nucleus Neurons: Electrophysiological Diversity and Essential Role in Arousal Stability. J. Neurosci. 2017, 37, 9574–9592.
    11. Xie, J.F.; Fan, K.; Wang, C.; Xie, P.; Hou, M.; Xin, L.; Cui, G.F.; Wang, L.X.; Shao, Y.F.; Hou, Y.P. Inactivation of the Tuberomammillary Nucleus by GABAA Receptor Agonist Promotes Slow Wave Sleep in Freely Moving Rats and Histamine-Treated Rats. Neurochem. Res. 2017, 42, 2314–2325.
    12. Yanovsky, Y.; Schubring, S.R.; Yao, Q.; Zhao, Y.; Li, S.; May, A.; Haas, H.L.; Lin, J.S.; Sergeeva, O.A. Waking action of ursodeoxycholic acid (UDCA) involves histamine and GABAA receptor block. PLoS ONE 2012, 7, e42512.
    13. Soares, R.; Ribeiro, F.F.; Xapelli, S.; Genebra, T.; Ribeiro, M.F.; Sebastiao, A.M.; Rodrigues, C.M.P.; Sola, S. Tauroursodeoxycholic Acid Enhances Mitochondrial Biogenesis, Neural Stem Cell Pool, and Early Neurogenesis in Adult Rats. Mol. Neurobiol. 2018, 55, 3725–3738.
    14. Bond, A.M.; Ming, G.L.; Song, H. Adult Mammalian Neural Stem Cells and Neurogenesis: Five Decades Later. Cell Stem Cell 2015, 17, 385–395.
    15. Holtzman, D.M.; Morris, J.C.; Goate, A.M. Alzheimer’s disease: The challenge of the second century. Sci. Transl. Med. 2011, 3, 77sr71.
    16. Cole, S.L.; Vassar, R. The Basic Biology of BACE1: A Key Therapeutic Target for Alzheimer’s Disease. Curr. Genom. 2007, 8, 509–530.
    17. Tomita, T. Molecular mechanism of intramembrane proteolysis by gamma-secretase. J. Biochem. 2014, 156, 195–201.
    18. Sun, L.; Zhao, L.; Yang, G.; Yan, C.; Zhou, R.; Zhou, X.; Xie, T.; Zhao, Y.; Wu, S.; Li, X.; et al. Structural basis of human gamma-secretase assembly. Proc. Natl. Acad. Sci. USA 2015, 112, 6003–6008.
    19. Lee, J.H.; Yu, W.H.; Kumar, A.; Lee, S.; Mohan, P.S.; Peterhoff, C.M.; Wolfe, D.M.; Martinez-Vicente, M.; Massey, A.C.; Sovak, G.; et al. Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell 2010, 141, 1146–1158.
    20. Nunes, A.F.; Amaral, J.D.; Lo, A.C.; Fonseca, M.B.; Viana, R.J.; Callaerts-Vegh, Z.; D’Hooge, R.; Rodrigues, C.M. TUDCA, a bile acid, attenuates amyloid precursor protein processing and amyloid-beta deposition in APP/PS1 mice. Mol. Neurobiol. 2012, 45, 440–454.
    21. Lo, A.C.; Callaerts-Vegh, Z.; Nunes, A.F.; Rodrigues, C.M.; D’Hooge, R. Tauroursodeoxycholic acid (TUDCA) supplementation prevents cognitive impairment and amyloid deposition in APP/PS1 mice. Neurobiol. Dis. 2013, 50, 21–29.
    22. Pan, X.; Elliott, C.T.; McGuinness, B.; Passmore, P.; Kehoe, P.G.; Holscher, C.; McClean, P.L.; Graham, S.F.; Green, B.D. Metabolomic Profiling of Bile Acids in Clinical and Experimental Samples of Alzheimer’s Disease. Metabolites 2017, 7, 28.
    23. Marksteiner, J.; Blasko, I.; Kemmler, G.; Koal, T.; Humpel, C. Bile acid quantification of 20 plasma metabolites identifies lithocholic acid as a putative biomarker in Alzheimer’s disease. Metabolomics 2018, 14, 1.
    24. MahmoudianDehkordi, S.; Arnold, M.; Nho, K.; Ahmad, S.; Jia, W.; Xie, G.; Louie, G.; Kueider-Paisley, A.; Moseley, M.A.; Thompson, J.W.; et al. Altered bile acid profile associates with cognitive impairment in Alzheimer’s disease-An emerging role for gut microbiome. Alzheimers Dement. 2019, 15, 76–92.
    25. Area-Gomez, E.; de Groof, A.; Bonilla, E.; Montesinos, J.; Tanji, K.; Boldogh, I.; Pon, L.; Schon, E.A. A key role for MAM in mediating mitochondrial dysfunction in Alzheimer disease. Cell Death Dis. 2018, 9, 335.
    26. Gao, J.; Wang, L.; Liu, J.; Xie, F.; Su, B.; Wang, X. Abnormalities of Mitochondrial Dynamics in Neurodegenerative Diseases. Antioxidants (Basel) 2017, 6, 25.
    27. Kiriyama, Y.; Nochi, H. Intra- and Intercellular Quality Control Mechanisms of Mitochondria. Cells 2018, 7, 1.
    28. Bell, S.M.; Barnes, K.; Clemmens, H.; Al-Rafiah, A.R.; Al-Ofi, E.A.; Leech, V.; Bandmann, O.; Shaw, P.J.; Blackburn, D.J.; Ferraiuolo, L.; et al. Ursodeoxycholic Acid Improves Mitochondrial Function and Redistributes Drp1 in Fibroblasts from Patients with Either Sporadic or Familial Alzheimer’s Disease. J. Mol. Biol 2018, 430, 3942–3953.
    29. Jankovic, J. Parkinson’s disease: Clinical features and diagnosis. J. Neurol. Neurosurg. Psychiatry 2008, 79, 368–376.
    30. Kiriyama, Y.; Nochi, H. The Function of Autophagy in Neurodegenerative Diseases. Int. J. Mol. Sci. 2015, 16, 26797–26812.
    31. Gladkova, C.; Maslen, S.L.; Skehel, J.M.; Komander, D. Mechanism of parkin activation by PINK1. Nature 2018, 559, 410–414.
    32. Hardy, J. Genetic analysis of pathways to Parkinson disease. Neuron 2010, 68, 201–206.
    33. Pickrell, A.M.; Youle, R.J. The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson’s disease. Neuron 2015, 85, 257–273.
    34. Heo, J.M.; Ordureau, A.; Paulo, J.A.; Rinehart, J.; Harper, J.W. The PINK1-PARKIN Mitochondrial Ubiquitylation Pathway Drives a Program of OPTN/NDP52 Recruitment and TBK1 Activation to Promote Mitophagy. Mol. Cell 2015, 60, 7–20.
    35. Lazarou, M.; Sliter, D.A.; Kane, L.A.; Sarraf, S.A.; Wang, C.; Burman, J.L.; Sideris, D.P.; Fogel, A.I.; Youle, R.J. The ubiquitin kinase PINK1 recruits autophagy receptors to induce mitophagy. Nature 2015, 524, 309–314.
    36. Martinez, T.N.; Greenamyre, J.T. Toxin models of mitochondrial dysfunction in Parkinson’s disease. Antioxid. Redox Signal. 2012, 16, 920–934.
    37. Connolly, N.M.C.; Theurey, P.; Adam-Vizi, V.; Bazan, N.G.; Bernardi, P.; Bolanos, J.P.; Culmsee, C.; Dawson, V.L.; Deshmukh, M.; Duchen, M.R.; et al. Guidelines on experimental methods to assess mitochondrial dysfunction in cellular models of neurodegenerative diseases. Cell Death Differ. 2018, 25, 542–572.
    38. Castro-Caldas, M.; Carvalho, A.N.; Rodrigues, E.; Henderson, C.J.; Wolf, C.R.; Rodrigues, C.M.; Gama, M.J. Tauroursodeoxycholic acid prevents MPTP-induced dopaminergic cell death in a mouse model of Parkinson’s disease. Mol. Neurobiol. 2012, 46, 475–486.
    39. Moreira, S.; Fonseca, I.; Nunes, M.J.; Rosa, A.; Lemos, L.; Rodrigues, E.; Carvalho, A.N.; Outeiro, T.F.; Rodrigues, C.M.P.; Gama, M.J.; et al. Nrf2 activation by tauroursodeoxycholic acid in experimental models of Parkinson’s disease. Exp. Neurol. 2017, 295, 77–87.
    40. Rosa, A.I.; Duarte-Silva, S.; Silva-Fernandes, A.; Nunes, M.J.; Carvalho, A.N.; Rodrigues, E.; Gama, M.J.; Rodrigues, C.M.P.; Maciel, P.; Castro-Caldas, M. Tauroursodeoxycholic Acid Improves Motor Symptoms in a Mouse Model of Parkinson’s Disease. Mol. Neurobiol. 2018, 55, 9139–9155.
    41. Rosa, A.I.; Fonseca, I.; Nunes, M.J.; Moreira, S.; Rodrigues, E.; Carvalho, A.N.; Rodrigues, C.M.P.; Gama, M.J.; Castro-Caldas, M. Novel insights into the antioxidant role of tauroursodeoxycholic acid in experimental models of Parkinson’s disease. Biochim. Biophys. Acta Mol. Basis Dis. 2017, 1863, 2171–2181.
    42. Abdelkader, N.F.; Safar, M.M.; Salem, H.A. Ursodeoxycholic Acid Ameliorates Apoptotic Cascade in the Rotenone Model of Parkinson’s Disease: Modulation of Mitochondrial Perturbations. Mol. Neurobiol. 2016, 53, 810–817.
    43. Dayalu, P.; Albin, R.L. Huntington disease: Pathogenesis and treatment. Neurol. Clin. 2015, 33, 101–114.
    44. The Huntington’s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 1993, 72, 971–983.
    45. Tunez, I.; Tasset, I.; Perez-De La Cruz, V.; Santamaria, A. 3-Nitropropionic acid as a tool to study the mechanisms involved in Huntington’s disease: Past, present and future. Molecules 2010, 15, 878–916.
    46. Li, J.Y.; Popovic, N.; Brundin, P. The use of the R6 transgenic mouse models of Huntington’s disease in attempts to develop novel therapeutic strategies. NeuroRx 2005, 2, 447–464.
    47. Keene, C.D.; Rodrigues, C.M.; Eich, T.; Linehan-Stieers, C.; Abt, A.; Kren, B.T.; Steer, C.J.; Low, W.C. A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington’s disease. Exp. Neurol. 2001, 171, 351–360.
    48. Mangiarini, L.; Sathasivam, K.; Seller, M.; Cozens, B.; Harper, A.; Hetherington, C.; Lawton, M.; Trottier, Y.; Lehrach, H.; Davies, S.W.; et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996, 87, 493–506.
    49. Keene, C.D.; Rodrigues, C.M.; Eich, T.; Chhabra, M.S.; Steer, C.J.; Low, W.C. Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington’s disease. Proc. Natl. Acad. Sci. USA 2002, 99, 10671–10676.
    50. Juenemann, K.; Jansen, A.H.P.; van Riel, L.; Merkx, R.; Mulder, M.P.C.; An, H.; Statsyuk, A.; Kirstein, J.; Ovaa, H.; Reits, E.A. Dynamic recruitment of ubiquitin to mutant huntingtin inclusion bodies. Sci. Rep. 2018, 8, 1405.
    51. Mancuso, R.; Navarro, X. Amyotrophic lateral sclerosis: Current perspectives from basic research to the clinic. Prog. Neurobiol. 2015, 133, 1–26.
    52. Renton, A.E.; Chio, A.; Traynor, B.J. State of play in amyotrophic lateral sclerosis genetics. Nat. Neurosci. 2014, 17, 17–23.
    53. De Giorgio, F.; Maduro, C.; Fisher, E.M.C.; Acevedo-Arozena, A. Transgenic and physiological mouse models give insights into different aspects of amyotrophic lateral sclerosis. Dis. Model. Mech 2019, 12.
    54. Muyderman, H.; Hutson, P.G.; Matusica, D.; Rogers, M.L.; Rush, R.A. The human G93A-superoxide dismutase-1 mutation, mitochondrial glutathione and apoptotic cell death. Neurochem. Res. 2009, 34, 1847–1856.
    55. Vaz, A.R.; Cunha, C.; Gomes, C.; Schmucki, N.; Barbosa, M.; Brites, D. Glycoursodeoxycholic acid reduces matrix metalloproteinase-9 and caspase-9 activation in a cellular model of superoxide dismutase-1 neurodegeneration. Mol. Neurobiol. 2015, 51, 864–877.
    56. Elia, A.E.; Lalli, S.; Monsurro, M.R.; Sagnelli, A.; Taiello, A.C.; Reggiori, B.; La Bella, V.; Tedeschi, G.; Albanese, A. Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis. Eur. J. Neurol. 2016, 23, 45–52.
    More